|
1
|
Griffiths TR; Action on Bladder Cancer:
Current perspectives in bladder cancer management. Int J Clin
Pract. 67:435–448. 2013. View Article : Google Scholar
|
|
2
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parekh DJ, Bochner BH and Dalbagni G:
Superficial and muscle-invasive bladder cancer: Principles of
management for outcomes assessments. J Clin Oncol. 24:5519–5527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gold LI: The role for transforming growth
factor-beta (TGF-beta) in human cancer. Crit Rev Oncog. 10:303–360.
1999.
|
|
5
|
Fabregat I, Fernando J, Mainez J and
Sancho P: TGF-beta signaling in cancer treatment. Curr Pharm Des.
20:2934–2947. 2014. View Article : Google Scholar
|
|
6
|
Katsuno Y, Lamouille S and Derynck R:
TGF-β signaling and epithelial-mesenchymal transition in cancer
progression. Curr Opin Oncol. 25:76–84. 2013. View Article : Google Scholar
|
|
7
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geng J, Fan J, Ouyang Q, Zhang X, Zhang X,
Yu J, Xu Z, Li Q, Yao X, Liu X, et al: Loss of PPM1A expression
enhances invasion and the epithelial-to-mesenchymal transition in
bladder cancer by activating the TGF-β/Smad signaling pathway.
Oncotarget. 5:5700–5711. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saitoh M: Epithelial-mesenchymal
transition is regulated at post-transcriptional levels by
transforming growth factor-β signaling during tumor progression.
Cancer Sci. 106:481–488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyazono K: Positive and negative
regulation of TGF-beta signaling. J Cell Sci. 113:1101–1109.
2000.PubMed/NCBI
|
|
11
|
Zeglinski MR, Hnatowich M, Jassal DS and
Dixon IM: SnoN as a novel negative regulator of TGF-β/Smad
signaling: A target for tailoring organ fibrosis. Am J Physiol
Heart Circ Physiol. 308:H75–H82. 2015. View Article : Google Scholar
|
|
12
|
Krakowski AR, Laboureau J, Mauviel A,
Bissell MJ and Luo K: Cytoplasmic SnoN in normal tissues and
nonmalignant cells antagonizes TGF-beta signaling by sequestration
of the Smad proteins. Proc Natl Acad Sci USA. 102:12437–12442.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tecalco-Cruz AC, Sosa-Garrocho M,
Vázquez-Victorio G, Ortiz-García L, Domínguez-Hüttinger E and
Macías-Silva M: Transforming growth factor-β/SMAD Target gene SKIL
is negatively regulated by the transcriptional cofactor complex
SNON-SMAD4. J Biol Chem. 287:26764–26776. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stroschein SL, Wang W, Zhou S, Zhou Q and
Luo K: Negative feedback regulation of TGF-beta signaling by the
SnoN oncoprotein. Science. 286:771–774. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ikeuchi Y, Dadakhujaev S, Chandhoke AS,
Huynh MA, Oldenborg A, Ikeuchi M, Deng L, Bennett EJ, Harper JW,
Bonni A, et al: TIF1γ protein regulates epithelial-mesenchymal
transition by operating as a small ubiquitin-like modifier (SUMO)
E3 ligase for the transcriptional regulator SnoN1. J Biol Chem.
289:25067–25078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu YH, Sarker KP, Pot I, Chan A,
Netherton SJ and Bonni S: Sumoylated SnoN represses transcription
in a promoter-specific manner. J Biol Chem. 281:33008–33018. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Johnson ES: Protein modification by SUMO.
Annu Rev Biochem. 73:355–382. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pot I and Bonni S: SnoN in TGF-beta
signaling and cancer biology. Curr Mol Med. 8:319–328. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Holz JD, Beier E, Sheu TJ, Ubayawardena R,
Wang M, Sampson ER, Rosier RN, Zuscik M and Puzas JE: Lead induces
an osteoarthritis-like phenotype in articular chondrocytes through
disruption of TGF-β signaling. J Orthop Res. 30:1760–1766. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Netherton SJ and Bonni S: Suppression of
TGFβ-induced epithelial-mesenchymal transition like phenotype by a
PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. PLoS
One. 5:e139712010. View Article : Google Scholar
|
|
22
|
Peng H, Feldman I and Rauscher FJ III:
Hetero-oligomerization among the TIF family of RBCC/TRIM
domain-containing nuclear cofactors: A potential mechanism for
regulating the switch between coactivation and corepression. J Mol
Biol. 320:629–644. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Yang K, Mao Q, Zheng X, Kong D and
Xie L: Inhibition of TGF-beta receptor I by siRNA suppresses the
motility and invasiveness of T24 bladder cancer cells via
modulation of integrins and matrix metalloproteinase. Int Urol
Nephrol. 42:315–323. 2010. View Article : Google Scholar
|
|
24
|
Zhao B and Chen YG: Regulation of TGF-β
signal transduction. Scientifica (Cairo). 2014:8740652014.
|
|
25
|
Imoto I, Pimkhaokham A, Fukuda Y, Yang ZQ,
Shimada Y, Nomura N, Hirai H, Imamura M and Inazawa J: SNO is a
probable target for gene amplification at 3q26 in squamous-cell
carcinomas of the esophagus. Biochem Biophys Res Commun.
286:559–565. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang F, Lundin M, Ristimäki A, Heikkilä
P, Lundin J, Isola J, Joensuu H and Laiho M: Ski-related novel
protein N (SnoN), a negative controller of transforming growth
factor-beta signaling, is a prognostic marker in estrogen
receptor-positive breast carcinomas. Cancer Res. 63:5005–5010.
2003.PubMed/NCBI
|
|
27
|
Jahchan NS, Ouyang G and Luo K: Expression
profiles of SnoN in normal and cancerous human tissues support its
tumor suppressor role in human cancer. PLoS One. 8:e557942013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
He W, Dorn DC, Erdjument-Bromage H, Tempst
P, Moore MA and Massagué J: Hematopoiesis controlled by distinct
TIF1γ and Smad4 branches of the TGFβ pathway. Cell. 125:929–941.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dupont S, Mamidi A, Cordenonsi M,
Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ,
Soligo S, Morsut L, et al: FAM/USP9x, a deubiquitinating enzyme
essential for TGFbeta signaling, controls Smad4 monoubiquitination.
Cell. 136:123–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jain S, Singhal S, Francis F, Hajdu C,
Wang JH, Suriawinata A, Wang YQ, Zhang M, Weinshel EH, Francois F,
et al: Association of overexpression of TIF1γ with colorectal
carcinogenesis and advanced colorectal adenocarcinoma. World J
Gastroenterol. 17:3994–4000. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ding ZY, Jin GN, Wang W, Chen WX, Wu YH,
Ai X, Chen L, Zhang WG, Liang HF, Laurence A, et al: Reduced
expression of transcriptional intermediary factor 1 gamma promotes
metastasis and indicates poor prognosis of hepatocellular
carcinoma. Hepatology. 60:1620–1636. 2014. View Article : Google Scholar : PubMed/NCBI
|
